Reducerea riscului cardiovascular: Prin reducerea greutii i mbuntirea profilului metabolic (glicemie, colesterol), Retatrutide poate reduce riscul de boli cardiovasculare, care sunt frecvent asociate cu obezitatea i diabetul
4 This type of medication was approved by the FDA in 2005 and is generally an injectable delivered in the fatty tissue present just under the skin.4 GLP-1 agonists are prescribed by a doctor who may decide that they are appropriate for an individual based on their specific needs
Weight Loss: While weight loss can be a desirable outcome for many individuals with type 2 diabetes, excessive weight loss associated with GLP-1 medications may be problematic for some patients, especially those who are already at a healthy weight or at risk of malnutrition
You will have a chance to ask any remaining questions , helping you make a quality decision for you and your health
One group had the GLP-1 system, plus a commercial protein powder
Marey A